Nominated IDE034 (BCG034) as a development candidate, a potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) Option exercised for an exclusive worldwide license for IDE034 from Biocytogen Targeting an IND-filing for IDE034 in 2025 to enable first-in-human clinical evaluation of B7H3/PTK7 topo-I-payload BsADC program IDE034 has the potential to be developed as a monotherapy and in combination with IDEAYA's PARG inhibitor IDE161 B7H3/PTK7 co-expression in lung, colorectal, and head and neck cancer, has been reported at approximately 30%, 46% and 27%, respectively SOUTH SAN FRANCISCO, Calif. and BEIJING , Nov. 11, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc.
(Nasdaq: IDYA ), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the selection of IDE034, a potential first-in-class B7H3/PTK7 topo-I-payload BsADC, as a development candidate and the exercise of its option for an exclusive worldwide license from Biocytogen Pharmaceuticals ( Beijing ) Co., Ltd. (Biocytogen, HKEX: 02315) for potential first-in-class B7H3/PTK7 BsADC program.
"We are pleased to nominate development candidate IDE034, a promising potential first-in class B7H3/PTK7 topo-I-payload bispecific ADC, which has demonstrated robust monotherapy tumor regressions in multiple preclinical models. The co-expression of B7H3/PTK7 in several solid tumors, including double-digit percent prevalence in lung, colorectal, and.
